SCAI Therapeutics Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 42

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $8.49M

  • Investors
  • 14

SCAI Therapeutics General Information

Description

Developer of a proprietary drug delivery platform designed to enhance the treatment of chronic diseases. The company's platform focuses on improving the bioavailability of therapeutic agents, treatments for dry eye syndrome and wet AMD, innovative cosmetic ingredients, facilitating effective drug administration, and addressing unmet medical needs, enabling healthcare providers to serve patients with serious conditions better while aiming to improve overall treatment outcomes.

Contact Information

Website
www.scaitrx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • A107, 17, Techno 4-ro
  • Yuseong-gu, Gwanpyeong-dong, Daedeok Biz Center
  • Daejeon, 34013
  • South Korea
+82
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Drug Delivery
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • A107, 17, Techno 4-ro
  • Yuseong-gu, Gwanpyeong-dong, Daedeok Biz Center
  • Daejeon, 34013
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SCAI Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 09-Jul-2026 $8.49M Completed Clinical Trials - General
3. Early Stage VC (Series B) 18-Jul-2021 Completed Clinical Trials - General
2. Early Stage VC (Series A) 31-Aug-2019 $6.61M $6.61M Completed Clinical Trials - General
1. Accelerator/Incubator Completed Clinical Trials - General
To view SCAI Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

SCAI Therapeutics Patents

  • 56

    Total Documents Applications and Grants

  • Total Patents Families

  • 9

    Granted

  • 30

    Pending

  • Expiring in next 12 mo

SCAI Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025230387-A1 Eye drop composition comprising novel molecular assembly of axitinib and preparation method therefor Pending 30-Apr-2024
US-20260108505-A1 Eye drop composition comprising novel molecular association of axitinib and method for preparing the same Pending 30-Apr-2024
EP-4656185-A1 Novel molecular assembly of axitinib Pending 12-Apr-2024
WO-2025216362-A1 Novel molecular assembly of axitinib Pending 12-Apr-2024
EP-4806420-A1 Polymer-containing composition having increased uv blocking boosting effect and cosmetic composition comprising same Pending 08-Mar-2024 A61K8/85
To view SCAI Therapeutics’s complete patent history, request access »

SCAI Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SCAI Therapeutics Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Access Ventures (Asia) Venture Capital Minority
BonAngels Venture Partners Venture Capital Minority
Positive Investment Venture Capital Minority
SOLiDX (South Korea) Corporate Venture Capital Minority
Forward Equity Partners PE/Buyout Minority
You’re viewing 5 of 14 investors. Get the full list »

SCAI Therapeutics Acquisitions (1)

SCAI Therapeutics’s most recent deal was a Merger/Acquisition with A-Stin. The deal was made on 01-Dec-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
A-Stin 01-Dec-2024 Merger/Acquisition Personal Products
To view SCAI Therapeutics’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

SCAI Therapeutics FAQs

  • When was SCAI Therapeutics founded?

    SCAI Therapeutics was founded in 2019.

  • Where is SCAI Therapeutics headquartered?

    SCAI Therapeutics is headquartered in Daejeon, South Korea.

  • What is the size of SCAI Therapeutics?

    SCAI Therapeutics has 42 total employees.

  • What industry is SCAI Therapeutics in?

    SCAI Therapeutics’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is SCAI Therapeutics a private or public company?

    SCAI Therapeutics is a Private company.

  • What is SCAI Therapeutics’s current revenue?

    The current revenue for SCAI Therapeutics is .

  • How much funding has SCAI Therapeutics raised over time?

    SCAI Therapeutics has raised $44.1M.

  • Who are SCAI Therapeutics’s investors?

    Access Ventures (Asia), BonAngels Venture Partners, Positive Investment, SOLiDX (South Korea), and Forward Equity Partners are 5 of 14 investors who have invested in SCAI Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process